Orasis Pharmaceuticals CEO Elad Kedar (L) and president and COO Paul Smith
Orasis snags $78M to launch presbyopia eye drops more than a year after FDA approval
Last October was an FDA approval. This October is a $68 million fundraising round. Next year, maybe a drug launch.
Orasis Pharmaceuticals …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
